TX-ONWARDMOBILITY
19.8.2020 14:03:11 CEST | Business Wire | Press release
OnwardMobility today announced agreements with BlackBerry (NYSE: BB; TSX:BB) and FIH Mobile Limited (HKG: 2038), a subsidiary of Foxconn Technology Group, to deliver a new 5G BlackBerry Android smartphone with physical keyboard, in the first half of 2021 in North America and Europe. Under the terms of the agreement, BlackBerry grants OnwardMobility the right to develop, engineer, and bring to market a BlackBerry 5G mobile device. Working closely with OnwardMobility, BlackBerry and FIH Mobile will ensure world-class design and manufacturing of these devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005202/en/
With the increasing number of employees working remotely with critical data and applications, coupled with the constant threat of cyberattacks, there is an absolute need for a secure, feature-rich 5G-ready phone that enhances productivity. Employees are demanding better workplace technology experiences, and organizations are facing increasingly complex challenges in selecting, deploying, securing and managing devices to meet expectations and maximize employee productivity.
“Enterprise professionals are eager for secure 5G devices that enable productivity, without sacrificing the user experience,” said Peter Franklin, CEO of OnwardMobility . “BlackBerry smartphones are known for protecting communications, privacy, and data. This is an incredible opportunity for OnwardMobility to bring next-generation 5G devices to market with the backing of BlackBerry and FIH Mobile.”
“Companies are rapidly investing in transformative technologies to improve productivity, but often don’t place enough emphasis on security, particularly in their use of mobile devices,” said analyst Jack Gold, President and Principal Analyst of J. Gold Associates, LLC. “With 5G quickly coming to market, and the acceleration it will cause in upgrading mobile devices and deploying productivity enhancing apps, deploying proven and highly secure products like the BlackBerry 5G devices in enterprises, government, and regulated industries like finance or legal, are mission critical."
“BlackBerry is thrilled OnwardMobility will deliver a BlackBerry 5G smartphone device with physical keyboard leveraging our high standards of trust and security synonymous with our brand. We are excited that customers will experience the enterprise and government level security and mobile productivity the new BlackBerry 5G smartphone will offer,” said John Chen, Executive Chairman and CEO, BlackBerry.
OnwardMobility will conduct product planning and market development for BlackBerry smartphones in North America and FIH Mobile will design and manufacture the BlackBerry devices under strict guidelines to ensure component, device and supply chain integrity.
“As an exclusive supplier to OnwardMobility, we’re committed to delivering new BlackBerry 5G devices to market, utilizing our deep expertise in design, manufacturing, component supply and logistics management,” said Dr. Wen-Yi Kuo, Executive Director, FIH Mobile.
Interested in learning more about OnwardMobility? Please visit: onwardmobility.com
- Potential financial partners may email: FinancialPartners@OnwardMobility.com .
- Businesses interested in ensuring access to early production or in pre-ordering devices may email: Contact@OnwardMobility.com .
- Those interested in working with OnwardMobility to solve today’s pressing security challenges may send resumes to: Recruiting@OnwardMobility.com .
About OnwardMobility
OnwardMobility is dedicated to producing the most productive, user-friendly and secure mobile devices for all businesses, from government to enterprise to those who power the gig economy. Security shapes every process involved in the development, design, supply chain sourcing and manufacture of all OnwardMobility devices. Our team is comprised of industry veterans and serial entrepreneurs with deep mobile, government and enterprise expertise. To learn more about our corporate mission, please visit: https://onwardmobility.com/ or follow us on Twitter , Facebook and LinkedIn .
About FIH Mobile Limited
As a subsidiary of Foxconn Technology Group and a leader in the mobile device industry worldwide, FIH offers a vertically integrated design, development, and manufacturing services, that is a comprehensive range of end-to-end engineering services and manufacturing services to its customers in respect of handsets, mobile/wireless communication devices and consumer electronic products. In light of moving into Internet era and exploring new business opportunities, FIH has also been engaged in 5G, IoV (Internet of Vehicle) and AI for building up the Internet and the mobile ecosystem. Visit our website at http://www.fihmb.com/
About BlackBerry
BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including 175M cars on the road today. Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety and data privacy solutions, and is a leader in the areas of endpoint security management, encryption, and embedded systems. BlackBerry’s vision is clear - to secure a connected future you can trust. For more information, visit BlackBerry.com and follow @BlackBerry .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005202/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom